Novartis: Swine flu vaccine tests ‘encouraging’
Geneva, September 03: Swiss pharmaceutical giant Novartis reported Thursday progress in clinical trials on a vaccine for swine flu saying one dose had led to successful immunization in 80 per cent of subjects.
Tests done on 100 healthy volunteers also reveled that 90 per cent became immune to swine flu if they were given two doses.
Novartis’ vaccine for the pandemic A(H1N1) virus, as swine flu is technically known, would be called Celtura, the company said in a statement.